Researchers found that peripheral injections of etanercept normalize the depressive effects of repeated steroid administration in an animal model.
There is a strong connection between the immune system and the brain in the context of depression. Chronic stress induces an inflammatory response in the body, which in the central nervous system includes an increase in pro-inflammatory cytokines. A recent study investigated whether peripheral injections of the anti—tumor necrosis factor (anti-TNF) inhibitor etanercept can help treat depression.
The study was conducted in an animal model comprising 24 male Long-Evans rats. The rats were randomly assigned to one of the following treatment groups:
All steroid and vehicle injections were administered once a day subcutaneously for 21 consecutive days. Etanercept and saline injections were given subcutaneously twice per week for 21 days. In addition, behavioral tests were conducted in the form of a forced swim test, an object-recognition memory test, and an object-in-place paradigm test.
The results of the experiment show that prolonged exposure to steroids produces a cluster of effects characterized by increased immobility in the swim test, impaired spatial memory on the object location and object-in-place tests, and reduced hippocampal neurogenesis. However, semi-weekly etanercept giving concurrently with steroids prevented all of these effects, which suggested that anti-TNF drugs could have a role in treating depression.
A particularly noteworthy finding of the study was that peripheral administration of etanercept restored steroid-induced deficits in hippocampal neurogenesis. However, the role of hippocampal neurogenesis in depression is a controversial issue, as the removal of hippocampal neurogenesis does not always induce depression-like behavior, and antidepressant effects can be seen without increases in neurogenesis.
The study also found that peripheral injections of etanercept normalize steroid-induced deficits in hippocampal reelin (a glycoprotein) expression. This idea comes from previous observations that reelin-overexpressing mice have increased neurogenesis, and that exogenous reelin can recover cognitive deficits in mouse models of both Angelman syndrome and Alzheimer disease. These observations correlate with the findings of this study that etanercept restores both object-location and object-in-place memory.
The researchers found that peripheral injections of etanercept normalize the depressive effects of repeated steroid administration. These results add to previous studies that suggested inflammatory events are a critical component of the pathogenesis of depression, and that there could be a key link between the immune system and the brain.
Reference
Brymer K, Fenton E, Kalychuk L, Caruncho H. Peripheral etanercept administration normalizes behavior, hippocampal neurogenesis, and hippocampal reelin and GABAA receptor expression in a preclinical model of depression [published online February 20, 2018]. Front Pharmacol. doi:10.3389/fphar.2018.00121.
The Top 5 Most-Read Gastroenterology Articles of 2024
December 21st 2024The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the year, while FDA and European approvals for ustekinumab biosimilars are set to improve access and reduce costs for patients with Crohn disease and ulcerative colitis.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.